openPR Logo
Press release

Liquid Biopsy Market - Insights

03-06-2018 03:42 PM CET | Health & Medicine

Press release from: Clinical Diagnostic Report By CMI

Liquid biopsy involves testing of the blood to identify biomarkers or cancer cells in the form of cells or pieces of DNA which are separated from the tumor and are circulating in the blood. Liquid biopsy helps in early detection of cancer, which would aid in adopting an optimal treatment plan. It is a non-invasive technique, which makes frequent testing possible, and effectiveness of cancer treatment can also be validated using it. The procedure requires only a small amount of blood sample of around 5 milliliters and the procedure is quicker, which is easily tolerated by the patients, making it a viable alternative for conventional biopsy techniques such as tissue biopsy. Liquid biopsy makes use of blood tests to identify presence of certain tumor cells such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes. Some of the commercially available liquid biopsy tests for cancer are Cologurad, Guardant360, Oncotype SEQ Liquid Select, and Target Selector liquid biopsy assays. However, in December 2017, two Johns Hopkins prostate cancer researchers found differences in the results from two different liquid biopsy providers and such inconsistencies in results may hinder the growth of the market.

Rising applications of liquid biopsy owing to its advantages over conventional biopsy is expected to boost growth of the liquid biopsy market

Liquid biopsy allows for efficient disease management as well as non-invasive prenatal testing (NIPT). Non–invasive prenatal testing enables diagnosis of potential risks of developing chromosomal abnormalities such as Edwards’s syndrome, Down syndrome, and X and Y chromosome abnormalities. It offers advantages such as frequent use with less risks as the sample is taken from blood only, offering complete genetic profile of the patient by providing DNA for more than one tumor; highly non-invasive technique; no biases in results, due to heterogeneity of the tumor tissues; requirement of small amount of sample; and cost and time effectiveness wherein, liquid biopsy addresses all these issues associated with conventional tissue biopsy. Furthermore, applications of liquid biopsy for diagnosis of non-small cell lung cancer (NSCLC), breast cancer, coronary heart disease, prostate cancer, etc. is increasing. For instance, according to a new study published in Oncology Journal, January 2018, the liquid biopsy combo involving exosomal RNA and cell-free DNA (cfDNA) improved the sensitivity of epidermal growth factor mutations in NSCLC. Furthermore, OncoCyte Corporation presented positive data from its breast cancer diagnostic test study, in December 2017, at San Antonio Breast Cancer Symposium.

The global liquid biopsy market was valued at US$ 1,824.7 million in 2016 and is expected to witness a robust CAGR of 18.3% over the forecast period (2017–2025).

Request For Sample Copy@
https://www.coherentmarketinsights.com/insight/request-sample/1223

Manufacturers are focusing on development of new tests in the liquid biopsy market and this is expected to bolster growth of the liquid biopsy market over the forecast period

Established as well as small players in the liquid biopsy market are actively focusing on research and development of methods in liquid biopsy through collaborations. For instance, Biodesix—a U.S.-based company—developed a novel way of extract circulating RNA from plasma in November 2017, in collaboration with Norgen Biotek. Moreover, Precipio—a U.S.-based organization, entered into merger agreement with Transgenomic, in 2017, for commercializing ICE COLD PCR (ICP) for liquid biopsies, which preferentially enriches mutant DNA sequences over wild-type DNA through selective amplification. HaploX Biotechnology—a China-based company—raised US$ 32 Mn in financing, in January 2018, in order to integrate liquid biopsy technology, artificial intelligence, and gene sequencing.

Furthermore, in May 2017, Guardant Health, Inc. raised US$ 360 million to create cancer blood tests to deploy its test for 1 million people over the next five years. Guardant Health and MD Anderson Cancer Center launched liquid biopsy partnership, in February 2017, under which Guardant is expected to help MD Anderson to build multiple on-site liquid biopsy centers. Guardant Health announced broad, long term alliance with Pfizer Oncology to support multiple clinical programs with its Guardant360 assay, in June 2017. Moreover, Guardant Health announced that it entered into separate agreements with AstraZeneca, Merck, Merck KGaA, and Darmstadt in January 2017 to develop 500 plus gene liquid biopsy panel to speed up clinical trials and drug development. Natera collaborated with Baylor Genetics to develop a non-invasive prenatal test, Vistara, in May 2017, which aided in detecting de novo mutations in single gene disorders.

Some major players operating in the liquid biopsy market include Illumina, Inc., Roche AG, Natera, Inc., Laboratory Corporation of America Holdings (LabCorp), Qiagen N.V., Thermo Fisher Scientific Inc., Exact Sciences Corp., Biocept, Inc., Genomic Health, Inc., Guardant Health, TrovaGene Inc., CareDx Inc., Adaptive Biotechnologies Corporation, and Biocartis SA.

Get More Details On this Report:
https://www.coherentmarketinsights.com/market-insight/liquid-biopsy-market-1223

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Liquid Biopsy Market - Insights here

News-ID: 966949 • Views: 284

More Releases from Clinical Diagnostic Report By CMI

Sepsis Diagnostic Market-Global Industry Insights, Trends, Outlook
Sepsis is life threatening complication caused due to the infection, which can result into organ failure, tissue damage, and ultimately lead to death if left untreated. If sepsis progresses to septic shock, it cause sudden drop in blood pressure and may leads to death of patient. Sepsis occurs due the infection in any part of the body. However the most common site of infections leading to the sepsis are lungs,
Enteric Disease Testing Market - Global Industry Insights 2025
Enteric infection is a type of intestinal disease that causes symptoms ranging from mild gastroenteritis to systemic infections and severe diarrhea. According to WHO in 2017, Infectious gastroenteritis accounts for 1 billion cases of diarrhea globally and over 2 million deaths annually. In addition to this, according to Bill and Melinda Gates Foundation, 2017, enteric and diarrheal diseases leads to death of about 500,000 children, under the age of five
Hospital Acquired Disease Testing Market to Surpass US$ 2.7 Billion by 2025 Glob …
Hospital acquired Disease Testing – Hospital or Mortuary Hospital acquired disease or nosocomial infection is a localized or systemic condition in patients occurred due to adverse reaction caused by infectious toxin agents under medical care and were absent at the time of admission. Hospitals acquired infections results in prolonged hospital stay, antimicrobial resistance, long-term disabilities, and increase mortality rate. Pathogens responsible for nosocomial infections include viruses, fungal parasites, and bacteria. Hospital acquired
In Vitro Diagnostics (IVD) Market Size to Soar Past US$ 25 Billion by 2024
In vitro diagnostics are diagnostic devices and equipment that extract vital information about an individual or patient after a sequence of tests. Introduction of novel diagnostics test applications on the backdrop of advancements and innovations in the IVD technologies by various organizations has resulted in rampant growth of the in vitro diagnostics (IVD) market, which is expected to sustain in the near future. Diagnoses and tests are precursors to any

All 5 Releases


More Releases for DNA

Recombinant DNA Technology Market -
Recombinant DNA technology has allowed the transfer of desired characteristics which is useful to improve the existing systems by controlling expression of target genes. Recombinant DNA technology allows mass production of therapeutic proteins, which are characterized by high level of consistency and stability. The technology has multidisciplinary applications and potential to deal with important aspects of life, for instance, improving health, and enhancing food resources. The genetically modified plants have
Synbio Technologies Revolutionizes DNA Synthesis
DNA Synthesis Definition and Methods DNA synthesis definition DNA synthesis is defined as the process by which copies of nucleic acids are strung together to form a longer DNA sequence within a laboratory setting. DNA synthesis processes DNA oligomers are the foundation of the DNA synthesis process. The essential feature of DNA synthesis is that no naturally isolated DNA is used. This step deviates from the traditional method of studying genetics, by which a
Global DNA Vaccine Pipeline Analysis
he global market for DNA vaccines is currently recording significant growth rates owing to the lesser side effects, ease of development, lesser cost and continued development in biotechnology arena. At present, not even a single DNA vaccine has been approved for human beings. However, around 100 products are under clinical trial for treating diseases like HIV infection, cancer and other infectious diseases. With regards to animal health, there are three
Global DNA Sequencing Market Report
MarketResearchReports.Biz announces addition of new report “Global DNA Sequencing Market Report: 2015 Edition” to its database. Description DNA sequencing market is one of the fastest growing segments of the life sciences tools market. This research study includes the market assessment of various products, technologies, applications and end-users. The report briefs about the classification in genomics, process of transcription and translation of DNA, historical development, and generations of sequencing technologies. The sequencing industry is
Global DNA Sequencing Market Report
MarketResearchReports.Biz announces addition of new report “Global DNA Sequencing Market Report: 2015 Edition” to its database. Description DNA sequencing market is one of the fastest growing segments of the life sciences tools market. This research study includes the market assessment of various products, technologies, applications and end-users. The report briefs about the classification in genomics, process of transcription and translation of DNA, historical development, and generations of sequencing technologies. The sequencing industry is
DNA Chip and DNA microarray industry NextGen Frontier for DNA Technologies – I …
A report from Transparency Market Research, titled ‘DNA Chip Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023,’ states that the global DNA chip market is expected to expand at a rapid pace during the period from 2015 to 2023 due to the increasing prevalence of cancer, the growth in personalized medicines, and technological advancements. A DNA chip, also known as a DNA microarray,